Table 2.
Baseline characteristics of early versus delayed 15-letter responders.
| Fixed monthly dosing | Less frequent dosing | |||||||
|---|---|---|---|---|---|---|---|---|
| ANCHOR | MARINA | PIER | SAILOR cohort 1 treatment-naïve at Baseline | |||||
| Early 15-letter | Delayed 15-letter | Early 15-letter | Delayed 15-letter | Early 15-letter | Delayed 15-letter | Early 15-letter | Delayed 15-letter | |
| responders | responders | responders | responders | responders | responders | responders | responders | |
| (n = 82) | (n = 41) | (n = 87) | (n = 77) | (n = 18) | (n = 6) | (n = 187) | (n = 57) | |
| Demographics | ||||||||
| Gender, % female | 46 | 54 | 63 | 66 | 39 | 50 | 56 | 51 |
| Age, mean years | 76 | 75 | 77 | 76 | 78 | 80 | 78 | 79 |
| VA, mean letters | 43* | 51 | 47* | 53 | 46 | 49 | 49 | 52 |
| Prior therapy for AMD,a % | 17 | 17 | 9 | 5 | 22 | 0 | 0 | 0 |
| Total area of, mean DA | ||||||||
| Lesion | 1.7 | 1.6 | 4.0 | 4.2 | 4.1 | 1.7 | NA | NA |
| CNV | 1.3 | 1.2 | 3.8 | 4.1 | 3.4 | 1.5 | NA | NA |
| Classic CNV | 1.1 | 1.1 | 0.2 | 0.2 | 0.7 | 0.1 | NA | NA |
| Classic CNV, % of lesion area | 65 | 69 | 5 | 4 | 32 | 14 | NA | NA |
| Leakage + RPE staining | 2.8 | 2.5 | 3.1 | 3.4 | 3.8 | 2.2 | NA | NA |
*P < 0.05 comparing early 15-letter responders versus delayed 15-letter responders.
AMD: age-related macular degeneration; CNV: choroidal neovascularization; DA: optic disk areas; NA: not available; RPE: retinal pigment epithelium; VA: visual acuity.
aPrior therapies for AMD included extrafoveal photodynamic therapy, laser photocoagulation (juxtafoveal or extrafoveal photocoagulation was allowed 1 month or more preceding day 0 in ANCHOR, MARINA, and PIER), and injections of triamcinolone acetonide and alteplase injection (intravitreal) to displace blood. Note: some study-eye prior therapies were excluded in the ANCHOR, MARINA, PIER, and SAILOR clinical trial protocols.